Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China

Meng-Meng Teng | Si-Ying Chen | Bo Yang | Yan Wang | Rui-Ying Han | Meng-Na An | Ya-lin Dong | Hai-Sheng You

1Department of Pharmacy, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
2Department of Pharmacy, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

Correspondence
Ya-lin Dong and Hai-Sheng You, Department of Pharmacy, The First Affiliated Hospital of Xi’an Jiaotong University, No.277, Yanta West Road, Xi’an, Shaanxi, 710061, PR China.
Email: dongyalin@xjtu.edu.cn and haishengyou77@163.com

Funding information
This work was supported by grants from the Science and Technology Development of Shaanxi Province, China (No. 2020SF-210), Clinical Research Award of the First Affiliated Hospital of Xi’an Jiaotong University, China (No. JXTU1AF-CRF-2019-006), and Institutional Foundation of the First Affiliated Hospital of Xi’an Jiaotong University, China (No. 2019QN-25).

Abstract

Background and Objective: The programmed death 1 and ligand (PD-1/PD-L1) inhibitors have significantly altered therapeutic perspectives on non-small-cell lung cancer (NSCLC). However, their efficacy and safety are unknown since direct clinical trials have not yet been performed on them. It is also necessary to determine the economics of PD-1/PD-L1 inhibitors due to their high cost. The aim was to evaluate the efficacy, safety, and cost-effectiveness of PD-1/PD-L1 inhibitor monotherapy for advanced NSCLC patients in China with high PD-L1 expression as first-line treatment.

Methods: From the PubMed, Cochrane, and Web of Science databases, we retrieved survival, progression, and safety data on PD-1/PD-L1 inhibitor monotherapy for advanced NSCLC patients. A network meta-analysis (NMA) was performed to consider PD-1/PD-L1 inhibitors in efficacy and safety. A Markov model with a full-lifetime horizon was adopted. Clinical and utility data were collected through the trial. The cost per quality-adjusted life year (QALY) was as incremental cost-effectiveness ratio (ICER). Sensitivity analyses were performed.

Results: This study included five phase III clinical trials using four drugs: nivolumab, pembrolizumab, atezolizumab, and durvalumab. The NMA demonstrated that the four drugs had similar efficacy and safety, while pembrolizumab and atezolizumab were better for than for nivolumab (hazard ratio (HR) = 0.66, 95% confidence intervals (CIs): 0.46–0.95 and HR = 0.59, 95%CI: 0.37–0.94) in progression-free survival (PFS), and the risk of a severe adverse event was higher for atezolizumab than for nivolumab and pembrolizumab. Compared with nivolumab, durvalumab, pembrolizumab, and atezolizumab had QALY of 0.19, 0.38, and 0.53, respectively, which induced ICERs of $197,028.8/QALY, $111,859.0/QALY, and $76,182.3/QALY, respectively.
1 INTRODUCTION

Lung cancer is the most common malignant cancer in the world, as well as the most common cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancers, and most NSCLC cases are locally advanced or metastatic at the time of diagnosis. Platinum-based chemotherapy is often recommended for advanced or metastatic NSCLC patients but has a survival rate lower than 20%, and therefore does not significantly prolong overall survival (OS). However, immunotherapy has shown enormous potential to further improve the prognosis for lung cancer patients, especially the programmed death 1 and ligand (PD-1/PD-L1) inhibitors.

The PD-1/PD-L1 inhibitors have rapidly received Food and Drug Administration agreement due to their strong clinical efficacy, longer survival, and less severe side effects. PD-1/PD-L1 inhibitors in several three-phase clinical trials prolonged survival times and decreased adverse events during NSCLC treatment, especially when patients had a high PD-L1 expression (≥50%). These results have greatly altered the conventional management of advanced or metastatic NSCLC. However, there is an absence of results directly comparing several different PD-1/PD-L1 inhibitors. Nevertheless, the cost of these breakthrough treatments must be considered.

Ensuring appropriate and sustainable use of targeted treatments for analyzing the efficacy, safety, and cost-effectiveness of PD-1/PD-L1 inhibitors on NSCLC is vital. This study investigated the efficacy, safety, and cost-effectiveness of PD-1/PD-L1 inhibitors as a first-line treatment for advanced or metastatic NSCLC with high-level PD-L1 expression.

2 METHODS

2.1 Network meta-analysis

Direct clinical trials are insufficient for PD-1/PD-L1-inhibitor monotherapy as a first-line treatment for advanced or metastatic NSCLC with high-level PD-L1 expression. A network meta-analysis (NMA) was therefore performed to evaluate the different PD-1/PD-L1 inhibitors in efficacy and safety. Two authors conducted independent reviews of PubMed, Cochrane Library, and Web of Science, published before January 1, 2021, using the search terms shown in supplement Table S1. The search term included “NSCLC,” “anti-PD-1,” “anti-PD-L1,” “first line,” “randomized controlled trial,” and so on. This analysis included randomized controlled trials with NSCLC eligible for first-line treatment. Eligible studies included patients with high-level PD-1 expression (≥50%), and PD-1/PD-L1 inhibitors monotherapy. Eligible studies were also required to report at least an assessment of survival (OS and PFS) and safety. The analysis excluded studies including patients with <18 years old, incomplete or duplicate data, and treatment which included PD-1/PD-L1 inhibitor combination with others drugs. The Cochrane risk of bias tool for randomized controlled trials was used to assess the quality and risk of bias of studies included in the analysis. The NMA was performed using graph theory implemented by the netmeta R package.

2.2 Analytical overview and model structure

We constructed a Markov model to determine the clinical and economic outcomes of PD-1/PD-L1 inhibitors as first-line treatments for advanced NSCLC, since this approach is effective for analyzing individual patient-level data. Virtual patient-level data were reconstructed. A hypothetical cohort about advanced NSCLC with high-level PD-L1 expression was constructed to compare the four potential competing targeted treatment drugs of nivolumab, pembrolizumab, atezolizumab, and durvalumab (Figure 1A). Health and economic outcomes were determined using a Markov model process which considered the three exclusive health states including progression-free disease (PFD), progressed disease (PD), and death. The Markov process was 21 days and PFD was the initial health state of all patients. The model was run until 99% of patients entered the death state with a lifetime horizon. The risk of
disease progression or death was determined by PFS and OS data from the NMA and previously published trials. The primary outcomes were quality-adjusted life year (QALY) and cost. Costs and QALY were reduced by 5% annually in line with Chinese guidelines for pharmacoeconomic evaluations. All costs are presented in 2020 US dollars. Incremental cost-effectiveness ratios (ICERs) were examined and presented as cost per QALY gained. We followed recommendations for the cost-effectiveness threshold of three times the per capita gross domestic product of China in 2020. We used three times the per capita gross domestic product of China in 2020 ($32,517.0) as the cost-effectiveness threshold according to the guideline recommendations.

### 2.3 Clinical data

We indirectly compared the survival rates of the four drugs. WebPlotDigitizer was used to construct Kaplan–Meier curves based on clinical data to project outcomes, and R package was used for fully parametric modeling of the survival data. Weibull survival models were fitted to the Kaplan–Meier survival curves for atezolizumab from IMpower 110 trial, which demonstrated the best fit for the Kaplan–Meier survival data. Table 1 lists the parameters of the estimated Weibull scale ($\lambda$) and shape ($\gamma$). The survival probability at time ($t$) was calculated using the following formula: $S(t) = P(T > t) = \exp(-\lambda t^\gamma)$. The transition probability from PFD to PS at a given cycle $t$ was calculated by using the Weibull scale ($\lambda$) and shape ($\gamma$). The other three drugs were derived using the adjusted Weibull scale and shape parameters. The hazard ratios (HRs) of PFS and OS were generated using NMA for these drugs relative to the atezolizumab strategy considered in the economic model.

### 2.4 Cost and utility data

Analyses were conducted from the perspective of the Chinese healthcare system. The direct medical costs were considered in the model, which included the drug costs, concomitant medication during therapy, management of severe adverse events (SAEs), routine follow-ups, and terminal care (Table 1). All costs were adjusted to 2020 US dollars using the local Consumer Price Index (1 US dollar = CNY ¥ 6.5).

### 2.5 Sensitivity analyses

We conducted the univariate and probabilistic sensitivity analyses. One-way sensitivity analysis tested the variance in potential parameter values of the models (Table 1). Probabilistic sensitivity analysis (PSA) was analyzed using
a Monte Carlo simulation, which incorporated the probability distribution including natural history parameters, HRs, costs, and utilities. Standard methods were adopted for defining uncertainty among parameters. The beta distribution was performed to the transition probability, proportion, and utility parameters, and the log-normal distribution to HRs parameters and costs. This study applied 10,000 replications to obtain a series of 10,000 outcome estimates. Cost-effectiveness acceptability curves (CEAC) presented the probability of a treatment being cost-effective against willingness-to-pay values.

### 3 | RESULT

#### 3.1 | Network meta-analysis

Because of the non-availability of direct head-to-head clinical trial data, an indirect comparison approach was conducted to evaluate the efficacy of PD-1/PD-L1 inhibitors as first-line treatments for advanced NSCLC with high-level PD-L1 expression. In total, 650 articles were screened from searches of the databases, after removing duplicates, screening of abstracts, and full-text article assessed, five articles met the full inclusion criteria (Supplementary Figure S1). The five clinical studies were the KEYNOTE-024, KEYNOTE-042, CheckMate-026, IMpower 110, and MYSTIC,\(^9,11–13,20\) for constructing the network, which all involved nivolumab, pembrolizumab, atezolizumab, or durvalumab. Study characteristics are summarized in Supplementary Table S2. In brief, all studies selected for inclusion were randomized controlled studies, three of the studies used double-blinding and two was open-label. Overall, the quality of the included studies was considered relatively low (Supplementary Figure S2). After HRs of OS, PFS, and adverse event data were extracted from these studies, the NMA was conducted based on a fixed-effects model to consider heterogeneity (\(I^2 = 13\%\)) (Figure 2). Figure 3 shows the HRs of OS and PFS, and risk rates (RR) of adverse events and SAE. PFS

| TABLE 1 | Cost and utility data |
|---------|----------------------|
| Parameters | Base | Range | Distribution | Reference |
| Cost (US $) | | | | |
| Pembrolizumab per cycle | 5386.7 | – | Fixed in PSA | Local |
| Atezolizumab per cycle | 4930.3 | – | Fixed in PSA | Local |
| Nivolumab per cycle | 4171.2 | – | Fixed in PSA | Local |
| Durvalumab per cycle | 6117.5 | – | Fixed in PSA | Local |
| Inpatient cost per cycle | 55.6 | 41.7–69.4 | Lognormal | \(^31\) |
| Progression disease treatment per cycle | 854.1 | 706.5–992.4 | Lognormal | \(^32\) |
| Best supportive care per cycle | 337.5 | 158.7–793.7 | Lognormal | \(^31\) |
| Terminal treatment per cycle | 2627.8 | 2291.8–2966.6 | Lognormal | \(^32\) |
| AEs managing cost per cycle | 362.2 | 271.6–452.7 | Lognormal | \(^32\) |
| Severe adverse events rate (%) | | | | |
| Nivolumab | 17.60 | – | Beta | \(^9\) |
| Pembrolizumab | 19.49 | – | Beta | \(^11,33\) |
| Atezolizumab | 30.07 | – | Beta | \(^12\) |
| Durvalumab | 14.90 | – | Beta | \(^13\) |
| Utility of health states per event | | | | |
| PFS | 0.804 | 0.643–0.965 | Beta | \(^34\) |
| PS | 0.321 | 0.257–0.385 | Beta | \(^34\) |
| Discount rate (%) | 5 | 0–8 | Fixed in PSA | \(^19\) |
| Weibull distribution parameters | | | | |
| Atezolizumab, OS, scale (Weibull), \(\lambda\) | 0.055227 | – | Fixed in PSA | \(^12\) |
| Atezolizumab, OS, shape (Weibull), \(\gamma\) | 0.724424 | – | Fixed in PSA | \(^12\) |
| Atezolizumab, PFS, scale (Weibull), \(\lambda\) | 0.119257 | – | Fixed in PSA | \(^12\) |
| Atezolizumab, PFS, shape (Weibull), \(\gamma\) | 0.701234 | – | Fixed in PSA | \(^12\) |

Abbreviations: HR: Hazard ratio; NMA: Network meta-analysis; OS: Overall survival; PFS: Progression-free survival; PS: Progression survival; PSA: Probabilistic sensitivity analysis.
was marginally better for pembrolizumab and atezolizumab than for nivolumab (HR = 0.66, 95% confidence intervals (CI): 0.46–0.95) and HR = 0.59, 95%CI: 0.37–0.94), whereas OS did not differ significantly between these two interventions (Figure 3A). Only atezolizumab had significant higher SAE safety outcomes than pembrolizumab (RR = 0.66, 95%CI: 0.46–0.95) and nivolumab (RR = 1.72, 95%CI: 1.22–2.43) (Figure 3B).

3.2 | Base-case analysis

Compared with nivolumab, durvalumab, pembrolizumab, and atezolizumab treatment strategies increased QALY by 0.19, 0.38, and 0.53, respectively, with incremental costs of $37,425.6, $42,108.1, and $39,758.9, which induced ICERs of $197,028.8/QALY, $111,859.0/QALY, and $76,182.3/QALY, respectively (Table 2). These results indicated that atezolizumab and pembrolizumab had better cost-effectiveness than durvalumab ($25,108.6 and $7,029.2 per QALY), and atezolizumab was a significant alternative to pembrolizumab based on the Chinese cost-effectiveness threshold ($32,517.0/QALY) (Table 2).

In Chinese health insurance, PD-1/PD-L1 inhibitors are the key items in insurance negotiations. The cost of these drugs will eventually reduce to 20% of the original cost. Therefore, to make accurate comparisons, the cost of each drug was reduced by 20%, 40%, 60%, and 80%. The results indicated that ICER gradually declined alongside costs. Other drugs such as atezolizumab and pembrolizumab might have advantages after cost reductions (Table 2).

3.3 | Sensitivity analysis

One-way sensitivity analyses indicated that the most influential parameters were the HRs of OS and PFS, utility, progression costs, and terminal treatment per cycle. However, adjusting these parameters might not yield substantial changes in ICER (Figure 4). The cost-effectiveness acceptability curve indicated that nivolumab was the optimal treatment in 97.5% of the iterations with the Chinese willingness-to-pay threshold (Figure 5).

4 | DISCUSSION

Cost-effectiveness analysis is a key driver when resources are allocated to fund innovations. Immunotherapy appears to be promising as an effective treatment for NSCLC, but also appears as an expensive alternative to the current
| Strategy name | Mean cost ($) | Effect QALY (Mean) | Compared with | Incremental cost ($) | Incremental QALY | ICER ($) | Rank |
|---------------|--------------|-------------------|--------------|---------------------|-----------------|----------|------|
| **Base cases** |              |                   |              |                     |                 |          |      |
| Nivolizumab   | 226,164.9    | 0.96              | Nivolizumab  | 37,425.6            | 0.19            | 197,028.8 | 1    |
| Durvalumab    | 263,590.5    | 1.15              | Nivolizumab  | 42,108.1            | 0.38            | 111,859.0 | 2    |
| Pembrolizumab | 268,273.0    | 1.34              | Durvalumab   | 4682.5              | 0.19            | 25,108.6  | 4    |
| Atezolizumab  | 265,923.7    | 1.49              | Nivolizumab  | 39,758.9            | 0.52            | 76,182.3  | 3    |
|               |              |                   | Durvalumab   | 2333.3              | 0.33            | 7029.2    |      |
|               |              |                   | Pembrolizumab| −2349.2             | 0.15            |          |      |

| **Price reduction** |              |                   |              |                     |                 |          |      |
| Drug cost reduced by 20% |              |                   |              |                     |                 |          |      |
| Nivolizumab   | 215,686.4    | 0.96              | Nivolizumab  | 27,977.0            | 0.19            | 147,286.1 | 1    |
| Durvalumab    | 243,663.4    | 1.15              | Nivolizumab  | 30,269.2            | 0.38            | 80,409.2  | 2    |
| Pembrolizumab | 245,955.5    | 1.34              | Durvalumab   | 2292.2              | 0.19            | 12,291.2  | 4    |
| Atezolizumab  | 242,730.3    | 1.49              | Nivolizumab  | 27,043.9            | 0.52            | 51,819.0  | 2    |
|               |              |                   | Durvalumab   | −933.1              | 0.33            | Dominated  |      |
|               |              |                   | Pembrolizumab| −3225.3             | 0.15            | Dominated  |      |

| Drug cost reduced by 40% |              |                   |              |                     |                 |          |      |
| Nivolizumab   | 205,207.9    | 0.96              | Nivolizumab  | 18,528.4            | 0.19            | 97,543.4  | 4    |
| Durvalumab    | 223,736.3    | 1.15              | Nivolizumab  | 18,430.2            | 0.38            | 48,959.4  | 3    |
| Pembrolizumab | 223,638.1    | 1.34              | Durvalumab   | −98.1               | 0.19            | Dominated  |      |
| Atezolizumab  | 219,536.8    | 1.49              | Nivolizumab  | 14,328.9            | 0.52            | 27,455.7  | 2    |
|               |              |                   | Durvalumab   | −4199.5             | 0.33            | Dominated  |      |
|               |              |                   | Pembrolizumab| −4101.3             | 0.15            | Dominated  |      |

| Drug cost reduced by 60% |              |                   |              |                     |                 |          |      |
| Nivolizumab   | 194,729.4    | 0.96              | Nivolizumab  | 9079.7              | 0.19            | 47,800.7  | 4    |
| Durvalumab    | 203,809.2    | 1.15              | Nivolizumab  | 6591.3              | 0.38            | 17,509.6  | 3    |
| Pembrolizumab | 201,320.7    | 1.34              | Durvalumab   | −2488.5             | 0.19            | Dominated  |      |
| Atezolizumab  | 196,343.3    | 1.49              | Nivolizumab  | 1613.9              | 0.52            | 3092.4    | 2    |
|               |              |                   | Durvalumab   | −7465.9             | 0.33            | Dominated  |      |
|               |              |                   | Pembrolizumab| −4977.4             | 0.15            | Dominated  |      |

| Drug cost reduced by 80% |              |                   |              |                     |                 |          |      |
| Nivolizumab   | 184,250.9    | 0.96              | Nivolizumab  | −368.9              | 0.19            | Dominated  | 3    |
| Durvalumab    | 183,882.1    | 1.15              | Nivolizumab  | −5247.7             | 0.38            | Dominated  | 2    |
| Pembrolizumab | 179,003.3    | 1.34              | Durvalumab   | −4878.8             | 0.19            | Dominated  | 1    |
| Atezolizumab  | 173,149.8    | 1.49              | Nivolizumab  | −11,101.1           | 0.52            | Dominated  | 1    |
|               |              |                   | Durvalumab   | −10,732.2           | 0.33            | Dominated  |      |
|               |              |                   | Pembrolizumab| −5853.5             | 0.15            | Dominated  |      |

Abbreviations: ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life years.
The PD-1/PD-L1 inhibitors clearly demonstrated an increase in life expectancy over the current chemotherapy standard, with an improved safety profile as a first-line treatment.21,12,13

NMAs were conducted to compare and benchmark the respective effectiveness and safety of pembrolizumab, nivolumab, atezolizumab, and durvalumab. The OS values of the results were similar among the four drugs, but pembrolizumab and atezolizumab had better PFS than nivolumab. Safety profiles indicated that atezolizumab had a higher risk of severe adverse events than pembrolizumab and nivolumab. However, effectiveness and safety were similar among the four drugs, which were not likely to optimize the dosage. Cost-effectiveness was therefore appropriate for distinguishing between the drugs. The ICERs of the lifetime horizons of durvalumab, pembrolizumab, and atezolizumab against nivolumab were estimated at $ 197,028.8/QALY, $ 111,859.0/QALY, and $ 76,182.3/QALY, respectively. Other regimens, especially pembrolizumab and durvalumab, were strictly dominated by atezolizumab.

This study is the first that we are aware of that has examined the cost-effectiveness of four competing, first-line PD-1/PD-L1 inhibitors that are licensed and recommended in current clinical guidelines. Our results will be greatly significant for addressing resource limitations in healthcare settings. Recent economic evaluations raised a controversy that pembrolizumab is more cost-effectiveness than chemotherapy in the first-line treatment of advanced NSCLC with high-level PD-L1 expression.22–24 Compared with chemotherapy, pembrolizumab has been indicated as cost-effectiveness for Swiss NSCLC patients, but unlikely to be cost-effectiveness for Singaporean NSCLC patients. Moreover, nivolumab and atezolizumab also showed similar results in comparison with chemotherapy in cost-effectiveness studies.15,25–27 Although the efficacy of PD-1/PD-L1 inhibitors is significantly greater than that of chemotherapy, their cost is currently higher, and does not provide benefits for some patients. High drug costs have become the main driver for limiting widespread immunotherapy use for cancer and bring great burdens on both the patients themselves and society as a whole.28 In other words, the benefits of immunotherapy depend on economics in addition to effectiveness and safety. However, no previous studies have investigated the optimal PD-1/PD-L1 inhibitor for immunotherapy in NSCLC.
patients. Additionally, the survival status of cancer patients changes over time, and it is therefore very important for economic analyses to appropriately simulate the survival status.\textsuperscript{29,30} The Kaplan–Meier survival curve can reflect the changes in the survival state over a period of time, but it is difficult to obtain the original data and evaluate the whole life cycle. Kaplan–Meier survival curves can reflect survival changes over time, but it is difficult to extract the original data and evaluate the entire life cycle. Therefore, according to current economic evaluations of chronic diseases such as cancer, the Markov model is often recommended to simulate changes in survival statuses during the life cycle.

This study is therefore derived from the real data of PFS and OS obtained from the IMpower 110 trial.\textsuperscript{12} Curve resimulation indicated that the model is better for clinical decision makers and management departments to refer to during relevant health decisions.

This study was subject to several limitations. First, due to the four investigated first-line regimes having no previous evaluations within one trial, an NMA was conducted for an indirect comparison. Second, a Weibull survival model was used to simulate the lifetime outcomes. Third, some key clinical input data, such as data on the strategies for the PD-1/PD-L1 inhibitors, were extracted from clinical reality in China. Finally, the safety data did not include the grade 1 to 2 adverse events of PD-1/PD-L1 inhibitors that are not currently accepted treatments.

\section*{5 | Conclusion}

In summary, the efficacy and safety of the four PD-1/ PD-L1 inhibitors analyzed in this study are similar. Only the OS was marginally better for pembrolizumab and atezolizumab than for nivolumab, and atezolizumab had significantly higher SAE safety outcomes than pembrolizumab and nivolumab. From the perspective of the Chinese healthcare system, nivolumab therapy is a cost-effective alternative to other drugs as first-line treatments for advanced NSCLC with high-level PD-L1 expression. Atezolizumab may be more cost-effective than pembrolizumab and durvalumab as a first-line treatment for locally advanced or metastatic NSCLC with high-level PD-L1 expression.
1. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1859–1922.

2. Wu B, Lu S. The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis. Transl Lung Cancer Res. 2020;9:1770–1784.

3. Al-Farsi A, Ellis PM. Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line. Front Oncol. 2014;4:157.

4. Thornton Snider J, Batt K, Wu Y, et al. The option value of innovation for non-small cell lung cancer and renal cell carcinoma. Am J Manag Care. 2017;23:e340–e346.

5. Li JX, Huang JM, Jiang ZB, et al. Current clinical progress of PD-1/PD-L1 immunotherapy and potential combination treatment in non-small cell lung cancer. Integr Cancer Ther. 2019;18:1534735419890020.

6. Kumar R, Collins D, Dolly S, et al. Targeting the PD-1/PD-L1 axis in non-small cell lung cancer. Curr Probl Cancer. 2017;41:111–124.

7. Leal TA, Ramalingam SS. Immunotherapy in previously treated non-small cell lung cancer (NSCLC). J Thorac Dis. 2018;10:5422–5432.

8. Lu J, Ramirez RA. The role of checkpoint inhibition in non-small cell lung cancer. Oncsner J. 2017;17:379–387.

9. Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376:2415–2426.

10. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–2028.

11. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–1833.

12. Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383:1328–1339.

13. Rizvi NA, Cho BC, Reimnuth N, et al. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6:661–674.

14. Kitadai R, Okuma Y, Hakozi T, et al. The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases. J Cancer Res Clin Oncol. 2020;146:777–785.

15. Giuliani J, Bonetti A. Immunotherapy in first-line for advanced non-small cell lung cancer: a cost-effective choice? Recenti Prog Med. 2019;110:138–143.

16. Chen R, Tao Y, Xu X, et al. The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer. Discov Med. 2018;26:155–166.

17. Almutairi AR, Alkhatib N, Martin J, et al. Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: a Bayesian network meta-analysis. Crit Rev Oncol Hematol. 2019;142:16–25.

18. Peters S, Reck M, Smit EF, et al. How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. Ann Oncol. 2019;30:884–896.

19. Xiao J, Sun JF, Wang QQ, Qi X, Yao HY. Health economic evaluation reporting guideline and application status. Zhonghua Yu Fang Yi Xue Za Zhi. 2017;51:276–280.

20. Wu B, Li TE, Cai J, et al. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. BMC Cancer. 2014;14:984.

21. Zeng X, Karnon J, Wang S, et al. The cost of treating advanced non-small cell lung cancer: estimates from the Chinese experience. PLoS One. 2012;7:e48323.

22. Mok TSK, Wu Y-L, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819–1830.

23. Nafees B, Lloyd AJ, Dewilde S, et al. Health state utilities in non-small cell lung cancer: an international study. Asia Pac J Clin Oncol. 2017;13:e195–e203.

24. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small cell lung cancer. N Engl J Med. 2018;378:2078–2092.

25. Globserv MA, Davies M. NCCN guidelines updates: new immuno-therapy strategies for improving outcomes in non-small cell lung cancer. J Natl Compr Canc Netw. 2019;17:574–578.

26. Aziz MIA, Tan LE, Tan WHG, et al. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer. J Med Econ. 2020;23:952–960.

27. Zhou K, Jiang C, Li Q. Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores. Lung Cancer. 2019;136:98–101.

28. Loong HH, Wong CKH, Leung LKS, et al. Cost effectiveness of PD-L1-based test-and-treat strategy with pembrolizumab as the first-line treatment for metastatic NSCLC in Hong Kong. Pharmacoecon Open. 2020;4:235–247.

29. Hu H, She L, Liao M, et al. Cost-effectiveness analysis of nivolumab plus ipilimumab vs. chemotherapy as first-line
therapy in advanced non-small cell lung cancer. *Front Oncol.* 2020;10:1649.

30. Lin S, Luo S, Zhong L, et al. Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer. *Int J Clin Pharm.* 2020;42:1175-1183.

31. Han J, Tian K, Yang J, et al. Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: an updated PACIFIC trial-based cost-effectiveness analysis. *Lung Cancer.* 2020;146:42-49.

32. Ding H, Xin W, Tong Y, et al. Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: a systematic review. *PLoS One.* 2020;15:e0238536.

33. Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. *BMC Med Res Methodol.* 2011;11:139.

34. Djalalov S, Beca J, Ewara EM, et al. A comparison of different analysis methods for reconstructed survival data to inform cost-effectiveness analysis. *Pharmaco economics.* 2019;37:1525-1536.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

---

**How to cite this article:** Teng M-M, Chen S-Y, Yang B, et al. Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China. *Cancer Med.* 2021;10:6344–6353. [https://doi.org/10.1002/cam4.4191](https://doi.org/10.1002/cam4.4191)